News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

"You need to find a vaccine that is durable, long-lasting," he said. "But you also, in real practical terms, need to find a vaccine you can manufacture in billions of doses at scale. And thirdly, you need to find a vaccine you can keep at room temperature. "This checks all those boxes. You can generate trillions of these EDVs and transfer this to under-developed countries, such as in Africa." But EngeneIC's technology has potential for so much more — able to fight other viruses and even the most drug-resistant cancer cells. As Dr Brahmbhatt explained, "This little nano cell can be loaded up with very toxic drugs and it only targets cancer cells — does not touch the normal cells in the body. "Therefore, there are no toxic side effects in our cancer patients. At the same time, it trains the immune system to be able to recognise those cancer cells and it specifically knocks it off."

"The other key positive of this new technology is it's cheaper and easier to make and deliver. "It can be freeze-dried and presented as a powder and you just add water," Dr MacDiarmid said. "And that means you take away all the cold chain. It can be sent out to remote spots, including to our indigenous communities."

"What he's most excited about is EngeneIC's unique COVID-19 vaccine. And here's why: The COVID-19 virus has what's known as spike proteins — raised bumps on its surface. Current vaccines use antibodies to target those spike proteins, but only have a few keys to latch on. Like Velcro, Engeneic's vaccine has many more keys, so sticky and strong it holds on no matter how much the virus mutates. "This is the first, I believe, COVID vaccine that will use this approach," Dr Soon-Shiong said. "And the preliminary data, clinical data and phase one data is incredibly promising." In trials with six healthy patients, the EDV vaccine neutralised 95 per cent of all current COVID-19 variants. But it hasn't yet been tested against the newest strain — Omicron. However, EngeneIC's scientists are now planning to send blood samples to South Africa, where Omicron was discovered, to determine how effective it will be. EngeneIC joint Chief Executive, Dr Himanshu Brahmbhatt, believes it will be effective. "These high-affinity antibodies are capable of locking on in such a way that it hangs on — no matter what mutant comes along," he said."

Small Sydney company strikes billion-dollar biotech deal for groundbreaking treatments https://www.9news.com.au/national/sydney-tech-company-strikes-biotech-deal-for-covid19-vaccine-and-cancer-treatment/58867647-97a5-4451-9975-91300ab487b5

Erste Human-Ergebnisse der Zusammenarbeit: https://www.globenewswire.com/news-release/2021/11/30/2342890/0/en/Australian-Biotech-EnGeneIC-Strikes-Landmark-Deal-with-Major-US-Biotech-ImmunityBio-for-COVID-19-Vaccine-and-Cancer-Treatment.html

Zusammenarbeit bekannt gegeben: https://www.bcm.edu/news/baylor-tch-and-immunitybio-collaborate-for-covid-19-vaccine-for-africa

PiperSandler 33rd Annual Healthcare Conference NOV 30 - DEC 2, 2021 https://ir.immunitybio.com/events/event-details/pipersandler-33rd-annual-healthcare-conference

Institutional Ownership and Shareholders Immunitybio Inc (US:IBRX) has 295 institutional owners and shareholders (aka shareholding pattern) that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 38,996,995 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, XBI - SPDR(R) S&P(R) Biotech ETF, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, Geode Capital Management, Llc, NAESX - Vanguard Small-Cap Index Fund Investor Shares, Northern Trust Corp, and Jpmorgan Chase & Co.

Videopräsentation zur Jefferies Healthcare Conference: https://immunitybio.com/jefferies-london-healthcare-conference/

T-Zellen kontrollieren Sars-CoV-2 Bei der Untersuchung stellten die Forscher fest, dass sich in 20 Blutproben erhöhte Werte bestimmter T-Zellen befanden. "Ich habe so etwas noch nie gesehen. Es ist wirklich überraschend, dass die T-Zellen eine Infektion so schnell kontrollieren können", wird Shane Crotty, Immunologe am La Jolla Institute for Immunology in Kalifornien, der nicht an der Forschung beteiligt war, bei "Nature" zitiert. Es scheint so zu sein, dass das Immunsystem dieser Menschen in der Lage ist, das Virus zu bekämpfen, bevor es sich festsetzen und weiterverbreiten kann. Ein solcher Vorgang wird in der Fachsprache als "abortive Infektion" bezeichnet. Die schnelle und effektive Abwehr könnte durch diese spezifischen T-Zellen, die auch als Gedächtniszellen bezeichnet werden, zustande kommen. Es könnte sein, dass das Immunsystem dieser Menschen bereits darauf vorbereitet war, die neue Krankheit zu bekämpfen, erklärt Leo Swadling vom University College London, der an der Studie beteiligt war, laut BBC. Die T-Zellen sind laut Forscher in der Lage, den Komplex aus mehreren Virus-Proteinen zu erkennen und zu bekämpfen, sodass die Vermehrung des Virus, der sogenannte Replikationskomplex, deaktiviert und damit völlig eingestellt wird. Die Forscher fanden diese T-Zellen nicht nur häufiger im Blut bei denjenigen, die keine Anzeichen für eine Infektion gezeigt hatten, sondern auch in Proben, die bereits vor der Pandemie genommen worden waren. Auszug aus: https://www.n-tv.de/22939523